BIOMAT Database Logo BIOMAT Database Logo

Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. 1995

E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Department of Human Biopathology, University, La Sapienza, Rome, Italy.

We report a case of therapy-related acute myeloid leukemia (t-AML), M4 FAB subtype, with t(10;11)(p14;q21) chromosome abnormality developed in a patient treated for acute promyelocytic leukemia (APL) after 4 years of continuous complete remission (CCR). Two distinct forms of t-AML have been described: the classical type and the second type. Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase. However, it differs in the chromosome 11 breakpoint (band q21 instead of q23) and absence of ALL-1 (Hrx, MLL, Htrx) gene involvement. This can represent the second observation of t-AML occurring after treatment for APL.

UI MeSH Term Description Entries
D007621 Karyotyping Mapping of the KARYOTYPE of a cell. Karyotype Analysis Methods,Analysis Method, Karyotype,Analysis Methods, Karyotype,Karyotype Analysis Method,Karyotypings,Method, Karyotype Analysis,Methods, Karyotype Analysis
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008942 Mitoxantrone An anthracenedione-derived antineoplastic agent. Mitozantrone,CL-232325,DHAQ,Mitoxantrone Acetate,Mitoxantrone Hydrochloride,Mitroxone,NSC-279836,NSC-287836,NSC-299195,NSC-301739,NSC-301739D,Novantron,Novantrone,Onkotrone,Pralifan,Ralenova,Acetate, Mitoxantrone,CL 232325,CL232325,Hydrochloride, Mitoxantrone,NSC 279836,NSC 287836,NSC 299195,NSC 301739,NSC 301739D,NSC279836,NSC287836,NSC299195,NSC301739,NSC301739D
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D002879 Chromosomes, Human, Pair 10 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 10
D002880 Chromosomes, Human, Pair 11 A specific pair of GROUP C CHROMOSOMES of the human chromosome classification. Chromosome 11
D002884 Chromosomes, Human, Pair 15 A specific pair of GROUP D CHROMOSOMES of the human chromosome classification. Chromosome 15
D002886 Chromosomes, Human, Pair 17 A specific pair of GROUP E CHROMOSOMES of the human chromosome classification. Chromosome 17
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide

Related Publications

E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-related acute myeloid leukemia and myelodysplasia after successful treatment of acute promyelocytic leukemia.
February 2002, Leukemia & lymphoma,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Secondary chronic myelomonocytic leukemia with monosomy 7 after successful treatment of acute promyelocytic leukemia.
May 2008, Pathologie-biologie,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Myelodysplastic syndrome following successful therapy of acute promyelocytic leukemia.
January 1997, Leukemia,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia.
May 2012, Leukemia & lymphoma,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-related acute promyelocytic leukemia.
June 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-related acute promyelocytic leukemia.
April 2011, Haematologica,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-related acute promyelocytic leukemia.
October 1993, Leukemia,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-related myelodysplastic syndrome with monosomy 5 and 7 following successful therapy for acute promyelocytic leukemia with anthracyclines.
December 2002, Leukemia & lymphoma,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
Therapy-Related Pure Erythroid Leukaemia with Complex Karyotype Following Successful Treatment for Acute Promyelocytic Leukaemia.
April 2021, Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion,
E Todisco, and A M Testi, and G Avvisati, and M L Moleti, and M Cedrone, and G Cimino, and F Mancini, and S Amadori, and F Mandelli
[Therapy-related chronic myelomonocytic leukemia secondary to acute promyelocytic leukemia in remission for 15 years: one case report].
August 2018, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Copied contents to your clipboard!